Faculty Profile
Dr. Daniels Gregory A. Daniels, Ph.D., M.D.
Assistant Clinical Professor of Medicine
Division of Hematology-Oncology
Office Address:
Division of Hematology-Oncology
University of California, San Diego
Moores UCSD Cancer Center
3855 Health Sciences Drive, MC-0987
La Jolla, CA 92093
gdaniels@ucsd.edu
Office: (858) 534-3804
FAX: (858) 822-6190
| Education/Training | Research Interests | Publications | Laboratory |
Education and Training
| BA | Biochemistry & Cellular Biology, University California, San Diego | 1982-1987 |
| MS | Biochemistry, University of California, San Diego | 1987-1988 |
| Ph.D | Cancer Biology, Stanford University | 1989-1997 |
| MD | USC School of Medicine | 1995-1999 |
| Resident | Mayo Clinic, Rochester MN | 1999-2002 |
| Fellowship | Medical Oncology, Mayo Clinic, Rochester, MN | 2002-2005 |
Research Interests
Dr. Daniels coordinates our clinical program in melanoma. His own research involves understanding the link between autoimmunity and tumor immunity in developing more effective and less toxic vaccines and immune stimulatory approaches for patients with melanoma.
Publications
Daniels GA, Drews G, Saier MH Jr. Properties of a Tn5 insertion mutant defective in the structural gene (fruA) pf the fructose-specific phosphotransferase system of rhodobacter capsulatus. J Bacteriol, 170(4):1698-1703, 1988.
Sair MH Jr., Daniels GA, Boerner P, Lin J. Neutral amino acid transport systems in animal cells: potential targets of oncogene action and regulators of cellular growth. J Membrane Biol, 104(1):1-20, 1988.
Yamada Y, Chang YY, Daniels GA, Wu LF, Tomich JM, Yamada M, Saier MH Jr. Insertion of the mannitol permease into the membrane of Escherichia coli. Possible involvement of an N-terminal amphiphilic sequence. J Biol Chem, 266(27):17863-17871, 1991.
Buhr A, Daniels GA, Erni B. The glucose transporter of Escherichia coli. Mutants with impaired translocation activity that retain phosphorylation activity. J Biol Chem 267(6):3847-3851, 1992.
Gallo ML, Pergola F, Daniels GA, Lieber MR. Distinct roles for RAG-1 in the initiation of V(D)J recombination and in the resolution of coding ends. J Biol Chem, 269:22188-22192, 1994.
Daniels GA, Lieber M. Strand specificity in the transcriptional targeting of recombination at immunoglobulin switch sequences. Proc Natl Acad Sci USA, 92(12):5625-5629, 1995.
Daniels GA, Lieber MR. RNA:DNA complex formation upon transcription of immunoglobulin switch regions: implications for the mechanism and regulation of class switch recombination. Nucleic Acids Res, 23(24):5006-5011, 1995.
Daniels GA, Lieber MR. Transcription targets recombination at immunoglobulin switch sequences in a strand-specific manner. Curr Topic Microbiol Immunol, 217:171-189, 1996.
Li J, Daniels GA, Lieber MR. Asymmetric mutation around the recombination break point of immunoglobulin class switch sequences on extrachromosomal substrates. Nucleic Acids Res, 24(11):2104-2111, 1996.
Toman PD, Pieper F, Sakai N, Karatzas C, Platenburg E, de Wit I, Samuel C, Dekker A, Daniels GA, Berg RA, Platenburg GJ. Production of recombinant human type I procollagen homotrimer in the mammary gland of transgenic mice. Transgenic Research, 8(6):415-427, 1999.
Toman PD, Chisholm G, McMullin H, Grier LM, Olsen DR, Kovach RJ, Leigh SD, Fong BE, Chang R, Daniels GA, Berg RA, Hitzeman RA. Production of recombinant human type I procollagen trimers using a four-gene expression system in the yeast Saccharomyces cerevisiae. J Biol Chem, 275(30):23303-23309, 2000.
Daniels GA, Galanis E. Immunotherapy of renal cell carcinoma by intratumoral administration by an IL-2 cDNA/DMREI/DOPA lipid complex. Curr Opin Mol Ther, 3:70-76, 2001.
Daniels GA, Adjei AA. Advances in systemic therapy of small-cell cancer of the lung. Future Drugs. 1:89-92, 2001.
Daniels GA, Sanchez-Perez L, Diaz RM. Kottke T, Thompson J, Lai M, Gough M, Karim M, Bushell A, Chong H, Melcher A, Harrington K, Vile RG. A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol, 22:1125-1132, 2004.
Sanchez-Perez L, Kittke T, Diaz RM, Ahmed A, Thompson J. Chong H, Melcher A, Holmen S, Daniels GA, Vile RG. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res, 65:2009-2017, 2005.
Sanchez-Perez L, Kottke T, Daniels GA, Diaz RM, Thompson J, Pulido J, Melcher A, Vile RG. Killing of normal melanocytes combined with heat shock protein 70 and
CD40L expression, cures large established melanomas. The Journal of Immunology, 177:4168-4177, 2006.
